Literature DB >> 1848662

Renal alpha 1-adrenergic receptor subtypes: MDCK-D1 cells, but not rat cortical membranes possess a single population of receptors.

K Klijn1, S R Slivka, K Bell, P A Insel.   

Abstract

Recent work has demonstrated that alpha 1-adrenergic receptors are composed of at least two subtypes, termed alpha 1a and alpha 1b. It has been proposed that these subtypes may be linked to distinct second messenger systems. In the current studies, we have compared the properties of alpha 1-adrenergic receptors in rat renal cortical membranes with those in MDCK-D1 cells, a clonal cell line derived from distal tubule/collecting duct. Competitive binding studies with [3H]prazosin and compounds [5-methylurapidil, (+)-niguldipine, WB4101, and oxymetazoline] that distinguish high affinity (alpha 1a) and low affinity (alpha 1b) sites indicated that rat renal cortical membranes contain about 50% of each class of site. In contrast, MDCK-D1 cells contained a single population of low affinity sites. 5-Methylurapidil, but not the other compounds, recognized binding sites in these cells with a substantially lower affinity than has been observed for the low affinity site in other tissues and in parallel studies with renal cortical membranes. [3H]Prazosin binding sites in these cells, as well as alpha 1-adrenergic receptor-mediated arachidonic acid release and phosphoinositide and phosphatidylcholine hydrolysis, were sensitive to inactivation by chloroethylclonidine (IC50 approximately 0.7 microM), as expected for alpha 1b receptors. However, alpha 1-adrenergic receptors of MDCK-D1 cells required extracellular calcium for biological response, unlike what has been hypothesized for the alpha 1b receptor subtype. These data indicate that the population of alpha 1-adrenergic receptors of distal tubule/collecting duct cells likely consists of receptors of the alpha 1b subtype. The low affinity binding of 5-methylurapidil and the requirement for extracellular calcium for biological response in these cells suggest that this receptor may not be identical to the alpha 1b receptor that has been observed in other systems.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1848662

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

1.  alpha1-Adrenoceptor-mediated phosphorylation of myosin in rat-tail arterial smooth muscle.

Authors:  M Mita; M P Walsh
Journal:  Biochem J       Date:  1997-11-01       Impact factor: 3.857

2.  Alpha 1A and alpha 1B-adrenoceptors enhance inositol phosphate generation in rat renal cortex.

Authors:  M C Michel; R Büscher; T Philipp; O E Brodde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-02       Impact factor: 3.000

Review 3.  cAMP and Epac in the regulation of tissue fibrosis.

Authors:  Paul A Insel; Fiona Murray; Utako Yokoyama; Silvia Romano; Hongruo Yun; Loren Brown; Aaron Snead; David Lu; Nakon Aroonsakool
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

4.  Rat pineal alpha 1-adrenoceptor subtypes: studies using radioligand binding and reverse transcription-polymerase chain reaction analysis.

Authors:  D Sugden; N Anwar; D C Klein
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

5.  Functional evidence equating the pharmacologically-defined alpha 1A- and cloned alpha 1C-adrenoceptor: studies in the isolated perfused kidney of rat.

Authors:  D R Blue; D W Bonhaus; A P Ford; J R Pfister; N A Sharif; I A Shieh; R L Vimont; T J Williams; D E Clarke
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

6.  Protein kinase C-dependent activation of cytosolic phospholipase A2 and mitogen-activated protein kinase by alpha 1-adrenergic receptors in Madin-Darby canine kidney cells.

Authors:  M Xing; P A Insel
Journal:  J Clin Invest       Date:  1996-03-01       Impact factor: 14.808

Review 7.  Renal alpha-adrenergic receptors and genetic hypertension.

Authors:  C A Jackson; P A Insel
Journal:  Pediatr Nephrol       Date:  1993-12       Impact factor: 3.714

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.